High drug prices and hospital payments will be in the crosshairs of the 2019 Trump administration and Congress. Policy makers aim to be even more aggressive than in the past in their efforts to lower health-care costs.
Shira Stein, who covers Capitol Hill and Medicare policy for Bloomberg Law, discusses these and other health-care issues that may dominate the headlines in the coming year.
Democrats in the House will examine allowing Medicare to negotiate prescription drug prices directly with drugmakers, and incoming Senate Finance Committee Chairman
For more stories, analysis and expertiseOR Request Trial